AML1/ETO and its function as a regulator of gene transcription via epigenetic mechanisms
Open Access
- 30 July 2021
- journal article
- review article
- Published by Springer Science and Business Media LLC in Oncogene
- Vol. 40 (38), 5665-5676
- https://doi.org/10.1038/s41388-021-01952-w
Abstract
The chromosomal translocation t(8;21) and the resulting oncofusion gene AML1/ETO have long served as a prototypical genetic lesion to model and understand leukemogenesis. In this review, we describe the wide-ranging role of AML1/ETO in AML leukemogenesis, with a particular focus on the aberrant epigenetic regulation of gene transcription driven by this AML-defining mutation. We begin by analyzing how structural changes secondary to distinct genomic breakpoints and splice changes, as well as posttranscriptional modifications, influence AML1/ETO protein function. Next, we characterize how AML1/ETO recruits chromatin-modifying enzymes to target genes and how the oncofusion protein alters chromatin marks, transcription factor binding, and gene expression. We explore the specific impact of these global changes in the epigenetic network facilitated by the AML1/ETO oncofusion on cellular processes and leukemic growth. Furthermore, we define the genetic landscape of AML1/ETO-positive AML, presenting the current literature concerning the incidence of cooperating mutations in genes such as KIT, FLT3, and NRAS. Finally, we outline how alterations in transcriptional regulation patterns create potential vulnerabilities that may be exploited by epigenetically active agents and other therapeutics.Funding Information
- DKTK
This publication has 136 references indexed in Scilit:
- ERG and FLI1 binding sites demarcate targets for aberrant epigenetic regulation by AML1-ETO in acute myeloid leukemiaBlood, 2012
- PRMT1 interacts with AML1-ETO to promote its transcriptional activation and progenitor cell proliferative potentialBlood, 2012
- Depletion of RUNX1/ETO in t(8;21) AML cells leads to genome-wide changes in chromatin structure and transcription factor bindingLeukemia, 2012
- Bortezomib interferes with C-KIT processing and transforms the t(8;21)-generated fusion proteins into tumor-suppressing fragments in leukemia cellsProceedings of the National Academy of Sciences of the United States of America, 2012
- The Leukemogenicity of AML1-ETO Is Dependent on Site-Specific Lysine AcetylationScience, 2011
- POU4F1 is associated with t(8;21) acute myeloid leukemia and contributes directly to its unique transcriptional signatureLeukemia, 2010
- PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitroBreast Cancer Research, 2009
- Dysregulation of the C/EBPα Differentiation Pathway in Human CancerJournal of Clinical Oncology, 2009
- TEAD mediates YAP-dependent gene induction and growth controlGenes & Development, 2008
- The p21Waf1 pathway is involved in blocking leukemogenesis by the t(8;21) fusion protein AML1-ETOBlood, 2007